0 Benign ovarian tumor serous 10 2 15.8   mucous 9 1     Age (years) < 50 12 8       ≥50 40 30     FIGO stage I/II 5/11 3/5       III/IV 24/12 19/11     Histological type Serous 30 21   Ovarian carcinoma

tissue   Mucous 22 17     Histological grade BAY 11-7082 G1 10 4       G2/G3 14/28 9/25     Ascites No 24 16       Yes 28 22     Lymph nodes metastasis No 32 20       Yes 20 18 73.1* * χ2 test. Compared with normal ovarian and benign ovarian tumor tissues P < 0.05. Figure 1 Immunohistochemistry analysis of MACC1 expression in different ovarian tissues. Normal ovary (A) and benign ovarian tumor (B) showed a lower staining of MACC1, but ovarian cancer (C) showed higher density staining (DAB staining, × 400). (D): Bar graphs show the positive rates of MACC1 protein. *P < 0.05 versus normal and benign ovarian tissues. Down-regulation of MACC1 expressions by RNAi After transfection GW3965 research buy 48 h, transfected cells with green fluorescence under fluorescence microscopy were observed (Figure 2). Expressions of MACC1 in stably transfected cells, which were selected by G418, were measured by RT-PCR and Western blot. Compared to control cells, levels of MACC1 mRNA and protein were significantly

down-regulated in OVCAR-3-s1, OVCAR-3-s2 and OVCAR-3-s3 cells, especially in OVCAR-3-s3 cells (Figure 3). According to these results, OVCAR-3-s3 cells which showed the highest inhibitory rate of MACC1 were used for further assay described below. Figure 2 Transfection of MACC1-shRNA into ovarian carcinoma OVCAR-3 cells. (A):

Normal OVCAR-3 cells under incandescent light (× 200). (B): After transfection 24 h, OVCAR-3-s3 cells under fluorescent light (× 100). (C): QNZ nmr Monoplast colony of OVCAR-3-s3 cells selected by G418 for three weeks (× 200). (D): G418 resistant OVCAR-3-s3 cell line (× 100). Figure 3 Down-regulation of MACC1 by MACC1-shRNA in ovarian carcinoma cells. The best inhibitory effects of MACC1 were identified in OVCAR-3-s3 cells by RT-PCR (A) 2-hydroxyphytanoyl-CoA lyase and Western blot (C), which were both performed for three times independently. Bar graphs show the relative expression levels of MACC1 mRNA (B) and protein (D).*P < 0.05 versus control groups. Inhibition of cell proliferation and colony formation by MACC1 RNAi According to Figure 4, the proliferation of OVCAR-3-s3 cells was obviously inhibited from the second day, when compared with control cells. There were no differences among OVCAR-3, OVCAR-3-neo and OVCAR-3-NC cells. In addition, OVCAR-3-s3 cells had lower rate of colony formation than control groups as shown in Figure 5. Thus, knockdown of MACC1 by RNAi could inhibit the growth of ovarian carcinoma cells. Figure 4 Suppression of proliferation by MACC1 RNAi in ovarian carcinoma cells measured by MTT assay. Obviously inhibitory effect of cell proliferation was observed from the second day after MACC1 knockdown.*P < 0.05 versus control groups. Figure 5 MACC1-shRNA inhibited the monoplast colony formation of ovarian carcinoma cells.